If youre unlucky enough to have a poisonous snake sink its fangs into you, your best hope is an antivenom, which has been made in the same way since Victorian times.
It involves milking snake venom by hand and injecting it into horses or other animals in small doses to evoke an immune response. The animals blood is drawn and purified to obtain antibodies that act against the venom.
Producing antivenom in this way can get messy, not to mention dangerous. The process is error prone, laborious and the finished serum can result in serious side effects.
Experts have long called for better ways to treat snake bites, which kill some 200 people a day.
Now finally scientists are applying stem cell research and genome mappingto this long-ignored field of research. They hope it will bring antivenom production into the 21st Century and ultimately save thousands, if not hundreds of thousands, of lives each year.
Researchers in the Netherlandshave created venom-producing glands from the Cape Coral Snake and eight other snake species in the lab, using stem cells. The toxins produced by the miniature 3-D replicas of snake glands are all but identical to the snakes venom, the team announced Thursday.
In a parallel breakthrough, scientists in India have sequenced the genome of the Indian cobra,one of the countrys big four snakes that are responsible for most of the50,000 snakebite deaths India sees a year.
Theyve really moved the game on, said Nick Cammack, head of the snakebite team at UK medical research charity Wellcome. These are massive developments because its bringing 2020 science into a field thats been neglected.
Hans Clevers, the principal investigator at the Hubrecht Institute for Developmental Biology and Stem Cell Research in Utrecht, never expected to be using his lab to make snake venom.
A decade ago,he invented the technique to make human organoids miniature organs made from the stem cells of individual patients. Theyve allowed doctors to test the specific effects of drugs safely outside the body, something that has revolutionized and personalized areas such as cancer treatment.
So why did he decide to culture a snake venom gland?
Clevers said it was essentially a whim of three PhD students working in his lab whod grown bored of reproducing mouse and human kidneys, livers and guts. I think they sat down and asked themselves what is the most iconic animal we can culture? Not human or mouse. They said its got to be the snake. The snake venom gland.
They assumed that snakes would have stem cells the same way mice and humans have stems cells but nobody had ever investigated this, said Clevers.
After sourcing some fertilized snake eggs from a dealer, the researchers found they were able to take a tiny chunk ofsnake tissue,containing stem cells, and nurture it in a dish with the same growth factor they used for human organoids albeit at a lower temperature to createthe venom glands. And they found that these snake organoids tiny balls just one millimeter wide produced the same toxins as the snake venom.
Open them up and you have a lot of venom. As far as we can tell, its identical. Weve compared it directly to the venom from the same species of snake and we find the exact same components, said Clevers, who was an author of the paper that published in thejournal Celllast week.
The team compared their lab-made venom with the real thing at the genetic level and in terms of function, finding that muscle cells stopped firing when exposed to their synthetic venom.
The current antivenoms available to us, produced in horses not humans, trigger relatively high rates of adverse reactions, which can be mild, like rash and itch, or more serious, like anaphylaxis. Its also expensive stuff. Wellcome estimate that one vial of antivenom costs $160, and a full course usually requires multiple vials.
Even if the people who need it can afford it most snakebite victims live in rural Asia and Africa the world has less than half of the antivenom stock it needs, according to Wellcome.Plus antivenoms have been developed for only around 60% of the worlds venomous snakes.
In this context, the new research could have far-reaching consequences, allowing scientists to create a biobank of snake gland organoids from the 600 or so venomous snake species that could be used to produce limitless amounts of snake venom in a lab, said Clevers.
The next step is to take all that knowledge and start investigating new antivenoms that take a more molecular approach, said Clevers.
To create an antivenom, genetic information and organoid technology could be used to make the specific venom components that cause the most harm and from them produce monoclonal antibodies, which mimic the bodys immune system, to fight the venom, a method already used in immunotherapy treatments for cancer and other diseases.
Its a great new way to work with venom in terms of developing new treatments and developing antivenom. Snakes are very difficult to look after, Cammack said, who was not involved with the research.
Clevers said his lab now plans to make venom gland organoids from the worlds 50 most venomous animals and they will share this biobank with researchers worldwide. At the moment, Clevers said they are able to produce the organoids at a rate of one a week.
But producing antivenomis not an area that pharmaceutical companies have traditionally been keen to invest in,Clevers said
Campaigners often describe snakebites as a hidden health crisis, with snakebites killing more people than prostrate cancer and choleraworldwide, Cammack said.
Theres no money in the countries that suffer. Dont underestimate how many people die. Sharks kill about 20 per year. Snakes kill 100,000 or 150,000, said Clevers.
Im a cancer researcher essentially and I am appalled by the difference in investment in cancer research and this research.
One challenge to making synthetic antivenom is the sheer complexity of how a snake disables its prey. Its venom contains several different components that have different effects.
Researchers in India have sequenced the genome of the Indian Cobra, in an attempt to decode the venom.
Published in thejournal Nature Geneticsearlier this month,its the most complete snake genome assembled and contains the genetic recipe for the snake venom, establishing the link between the snakes toxins and the genes that encode them. Its not a straightforward cocktail the team identified 19 genes out of 139 toxin genes as the ones responsible for causing harm in humans.
Its the first time a very medically important snake has been mapped in such detail, said Somasekar Seshagiri, president of SciGenom Research Foundation, a nonprofit research center in India.
It creates the blueprint of the snake and helps us get the information from the venom glands. Next, his team will map the genomes of the saw-scaled viper, the common krait and the Russells viper the rest of Indias big four.This could help make antivenom from the glands as it will be easier to identify the right proteins.
In tandem, both breakthroughs will also make it easier to discover whether some of the potent molecules contained in snake venom are themselves worth prospecting as drugs allowing snakes to make their mark on human health in a different way to how nature intended by saving lives.
Snake venom has been used to make drugsthat treat hypertension (abnormally high blood pressure) and heart conditions such as angina.
As well as being scary, venom is amazingly useful, Seshagari said.
- Mount Sinai Leading the Way in Innovative Stem Cell Therapy for COVID-19 Patients - Newswise - April 9th, 2020
- First Stem Cell Clinical Trial for Protection Against COVID-19 Approved by FDA - HospiMedica - April 9th, 2020
- Moving toward Nonchemotherapy-Based Approaches in Follicular Lymphoma - Cancer Network - April 9th, 2020
- Seneca Biopharma Announces Results of Meeting with FDA Regarding the Design of Phase 3 Trial for NSI-566 in ALS - P&T Community - April 9th, 2020
- Immunotherapy After Chemotherapy Improves Outcomes in Metastatic Bladder Cancer - Curetoday.com - April 9th, 2020
- Celularity Expands Strategic Collaboration with United Therapeutics Corporation to COVID-19 Infection and Acute Respiratory Distress Syndrome - Yahoo... - April 9th, 2020
- UCSD To Advance Stem Cell Therapies in New Space Station Lab - Technology Networks - April 9th, 2020
- Convalescent plasma therapy useful in treating COVID-19 - Anadolu Ajans - April 9th, 2020
- Stempeutics partners with Global Consortium of cell therapy companies - BSI bureau - April 9th, 2020
- DNA Repair Gene-Related CHIP Is a Marker for Worse Outcomes in Patients With Lymphoma - Cancer Therapy Advisor - April 9th, 2020
- Canadian Company STEMCELL Technologies Is an Essential Industry Partner for COVID-19 Research and Vaccine Development - Financial Post - April 8th, 2020
- SNUH team finds causal gene of inherited retinal disorder - Korea Biomedical Review - April 8th, 2020
- FDA Accepts IND for NK Cell Therapy CYNK-001 to Treat Patients with COVID-19 - Cancer Network - April 8th, 2020
- Fate Therapeutics Strikes Multi-Billion Dollar Cell Therapy Deal with Janssen - BioSpace - April 8th, 2020
- Beam Therapeutics Licenses SIRION Biotech's LentiBOOST Technology for its CAR-T pipeline - Business Wire - April 8th, 2020
- COVID-19 Impact on Stem Cell Therapy Identify Which Types of Companies Could Potentially Benefit or Loose out From the Impact of COVID-19 - Science... - April 8th, 2020
- Nurses life-saving stem cell transplant leaves her with an addiction to Monster Munch just like her don - The Sun - April 8th, 2020
- Covid-19 Impact on Cell Freezing Media for Cell Therapy Market (2020-2026) - Science In Me - April 8th, 2020
- CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19) - GlobeNewswire - April 8th, 2020
- Coronavirus Update: Cell Therapy Reportedly Appears Promising To Beat COVID-19 - International Business Times - April 7th, 2020
- panCELLa receives research and development support for cell therapy - Yahoo Finance - April 7th, 2020
- Relief Therapeutics (RLF:SIX) Drug Aviptadil Enters FDA Trial at University of Miami, to Treat COVID-19-induced Respiratory Distress - Yahoo Finance - April 7th, 2020
- Stempeutics partners with Global Consortium of cell therapy companies - Express Healthcare - April 7th, 2020
- CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19) - BioSpace - April 7th, 2020
- Stem Cell Network Warns that Claims of Stem Cell Treatments for COVID-19 Are Unfounded and Misleading - Benzinga - April 2nd, 2020
- FibroGenesis Files Expanded Patent Coverage for its Fibroblast Cell Therapy to treat Coronavirus (COVID-19) ARDS - Yahoo Finance - April 2nd, 2020
- Cork man shares hacks for isolation that stopped him from 'going insane' - Echo Live - April 2nd, 2020
- Notice Regarding Business Alliance Between Sanbio and Ocumension in the Research, Development and Commercialization of Innovative Stem Cell Therapies... - April 2nd, 2020
- Designer, injectable gels to prevent transplanted Schwann cell loss during spinal cord injury therapy - Science Advances - April 2nd, 2020
- David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer - GlobeNewswire - April 2nd, 2020
- Global Cell Therapy Technologies Market : Industry Analysis and Forecast (2019-2026) - Publicist360 - April 2nd, 2020
- CytoDyn Files a Clinical Trial Protocol with the FDA to Treat Severely Ill COVID-19 Patients with Leronlimab where the Primary Endpoint is Mortality... - April 2nd, 2020
- Stem Cell Network Warns that Claims of Stem Cell Treatments for COVID-19 Are Unfounded and Misleading - GlobeNewswire - March 31st, 2020
- ElevateBio reels in $170M to push 6 cell, gene therapy programs - FierceBiotech - March 31st, 2020
- Stem Cells, Nerves Found to Interact in Cancer Progression - Pharmacy Times - March 31st, 2020
- Canine Stem Cell Therapy Market by Players, Types and Applications with In-Depth Research On Industry Size ... - The Financial News Daily - March 31st, 2020
- Blood donors in high demand - Dominion Post - The Dominion Post - March 29th, 2020
- Reversing The Ageing Process With Stem Cell Therapy - Version Weekly - March 29th, 2020
- Positive Opinion from European Medicines Agency for Sanofi's Isatuximab in R/R Multiple Myeloma - OncoZine - March 28th, 2020
- Global Autologous Cell Therapy Market 2020-2024 | Evolving Opportunities with Bayer AG and Brainstorm Cell Therapeutics Inc. | Technavio - Business... - March 28th, 2020
- Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2020-2024 | Evolving Opportunities with AllCells Corp. and bluebird bio Inc. | Technavio... - March 28th, 2020
- HIV/AIDS cure: Second patient confirmed HIV-free and here's the treatment that cured him - EconoTimes - March 28th, 2020
- Donald Trump Is Using An Insanely Sketchy Newsletter To Find Campaign Donors - The Union Journal - March 28th, 2020
- Stem Cell Alopecia Treatment Market 2020 | Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and Expected Revenue by 2026 -... - March 28th, 2020
- Canine Stem Cell Therapy Market Dynamics, Segments and Supply Demand 2029 - Packaging News 24 - March 28th, 2020
- Global Stem Cell and Gene Therapy Biological Testing Market (2019 to 2025) - Potential Growth Opportunities and Areas of Focus -... - March 27th, 2020
- Non-Profit Offers Free Stem Cell Therapy to Veterans - Pain News Network - March 27th, 2020
- Vitro Biopharma First Quarter ended January 31, 2020 Financial Results of Operations - Yahoo Finance - March 27th, 2020
- Kalytera Therapeutics: improving bone marrow transplants with CBD - Health Europa - March 27th, 2020
- A new way to study HIV's impact on the brain - Penn: Office of University Communications - March 27th, 2020
- HKBU Collaborates with Golden Meditech to Conduct Cell Therapy Research - QS WOW News - March 27th, 2020
- Medigene Provides Results for Fiscal Year 2019 and Outlook - Yahoo Finance - March 26th, 2020
- What Does It Mean to Be Immunocompromised? - Dana-Farber Cancer Institute - March 26th, 2020
- Oscar Saxelby-Lee gets 'super cells' after having stem cell transplant from dad to fight off cancer - Ledbury Reporter - March 26th, 2020
- Study Shows Development of Young Cells Could be New Option in Cancer Care - BioSpace - March 26th, 2020
- Bone Therapeutics appoints Stefanos Theoharis as Chief Business Officer - Yahoo Finance - March 26th, 2020
- Uni kit to help with virus tests - Kent Online - March 26th, 2020
- Old human cells rejuvenated with stem cell technology - Stanford Medical Center Report - March 25th, 2020
- Can cell-based therapy be helpful in tackling coronavirus? - YourStory - March 25th, 2020
- YOUR HEALTH: A rare disease that hardens the skin - WQAD.com - March 25th, 2020
- Rationales for Selecting CD19-Targeted Therapy in R/R B-Cell ALL - Cancer Therapy Advisor - March 25th, 2020
- Stem Cell Alopecia Treatment Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Bandera County Courier - March 24th, 2020
- Global Autologous Cell Therapy Market 2020-2024 | Evolving Opportunities with Bayer AG and Brainstorm Cell Therapeutics Inc. | Technavio - Yahoo... - March 24th, 2020
- Clinical trial to find effective Covid-19 treatments gets underway - Nursing Times - March 24th, 2020
- Pipeline: Investigational Therapies for COVID-19 - The Cardiology Advisor - March 24th, 2020
- Mentoring is a gift, asking for help a blessing - The Jewish News of Northern California - March 24th, 2020
- The Global Autologous Cell Therapy Market is expected to grow by USD 1.97 bn during 2020-2024, progressing at a CAGR of 22% during the forecast period... - March 24th, 2020
- The Forefront of Treating Hair Loss in Women - Yahoo Lifestyle - March 24th, 2020
- Two Additional Coronavirus Patients Treated at Leading New York Hospital with CytoDyn's Leronlimab, Bringing the Total to Four Patients - Associated... - March 24th, 2020
- Regulatory authorities approve JTA Phase III study in osteoarthritic knee pain and ALLOB Phase IIb study in difficult fractures | DNA RNA and Cells |... - March 24th, 2020
- Platelet Rich Plasma and Stem Cell Alopecia Treatment size in terms of volume and value 2019-2022 - Daily Science - March 24th, 2020
- Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates - GlobeNewswire - March 24th, 2020
- Stem Cell Alopecia Treatment Market Booming by Size, Revenue and Top Growing Companies APEX Biologix, Belgravia Center, RepliCel, Riken Research... - March 20th, 2020
- His Immune System Went Out of Whack. The Usual Treatment Didnt Work. Why? - The New York Times - March 18th, 2020
- China reports new progress in drug, therapies against Covid-19 - The Star Online - March 18th, 2020
- Imfinzi in Combination with Standard-of-Care Chemotherapies Improves Survival in Lung Cancer - Curetoday.com - March 18th, 2020
- What Are Drug Prevention and Treatment Options for COVID-19? - Pharmacy Times - March 18th, 2020
- Tessa Therapeutics to launch first CAR-T therapy for Hodgkin's lymphoma (HL) - BSA bureau - March 18th, 2020
- Orchard Therapeutics Appoints Company Founder and Gene Therapy Pioneer Bobby Gaspar, MD, Ph.D., as New Chief Executive Officer - BioSpace - March 18th, 2020
- Fate Therapeutics: Potential Catalysts Ahead - Seeking Alpha - March 18th, 2020